Vitrolife AB
STO:VITR
Intrinsic Value
Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. [ Read More ]
The intrinsic value of one VITR stock under the Base Case scenario is 143.96 SEK. Compared to the current market price of 177.5 SEK, Vitrolife AB is Overvalued by 19%.
Valuation Backtest
Vitrolife AB
Run backtest to discover the historical profit from buying and selling VITR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Vitrolife AB
Current Assets | 2B |
Cash & Short-Term Investments | 947m |
Receivables | 645m |
Other Current Assets | 456m |
Non-Current Assets | 14.8B |
Long-Term Investments | 56m |
PP&E | 368m |
Intangibles | 14.3B |
Other Non-Current Assets | 131m |
Current Liabilities | 556m |
Accounts Payable | 164m |
Accrued Liabilities | 178m |
Other Current Liabilities | 214m |
Non-Current Liabilities | 3.1B |
Long-Term Debt | 2B |
Other Non-Current Liabilities | 1.1B |
Earnings Waterfall
Vitrolife AB
Revenue
|
3.5B
SEK
|
Cost of Revenue
|
-1.5B
SEK
|
Gross Profit
|
2B
SEK
|
Operating Expenses
|
-5.6B
SEK
|
Operating Income
|
-3.6B
SEK
|
Other Expenses
|
-255m
SEK
|
Net Income
|
-3.8B
SEK
|
Free Cash Flow Analysis
Vitrolife AB
VITR Profitability Score
Profitability Due Diligence
Vitrolife AB's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Vitrolife AB's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
VITR Solvency Score
Solvency Due Diligence
Vitrolife AB's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Vitrolife AB's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VITR Price Targets Summary
Vitrolife AB
According to Wall Street analysts, the average 1-year price target for VITR is 233.33 SEK with a low forecast of 212.1 SEK and a high forecast of 278.25 SEK.
Shareholder Return
VITR Price
Vitrolife AB
Average Annual Return | 23.99% |
Standard Deviation of Annual Returns | 88.76% |
Max Drawdown | -77% |
Market Capitalization | 24B SEK |
Shares Outstanding | 135 447 008 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 427 full-time employees. The company went IPO on 2001-06-26. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. The company also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The firm is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Contact
IPO
Employees
Officers
The intrinsic value of one VITR stock under the Base Case scenario is 143.96 SEK.
Compared to the current market price of 177.5 SEK, Vitrolife AB is Overvalued by 19%.